TY - JOUR
T1 - Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-γ and breast milk transforming growth factor-β and immunoglobin A detection
AU - Prescott, Susan
AU - Wickens, K.
AU - Westcott, L.
AU - Jung, W.
AU - Currie, Helen
AU - Black, P.N.
AU - Stanley, T.V.
AU - Mitchell, E.A.
AU - Fitzharris, P.
AU - Siebers, R.
AU - Wu, L.
AU - Crane, J.
PY - 2008
Y1 - 2008
N2 - Background This study explored the effects of maternal probiotic supplementation on immune markers in cord blood (CB) and breast milk.Methods CB plasma and breast milk samples were collected from a cohort of women who had received daily supplements of either 6 x 10(9) CFU/day Lactobacillus rhamnosus HN001 (n = 34), 9 x 10(9) CFU/day Bifidobacterium lactis HN019 (n = 35) or a placebo (n = 36) beginning 2-5 weeks before delivery and continuing for 6 months in lactating women. CB plasma and breast milk (collected at 3-7 days, 3 months and 6 months postpartum) were assayed for cytokines (IL-13, IFN-gamma, IL-6, TNF-alpha, IL-10, TGF-beta 1) and sCD 14. Breast milk samples were also assayed for total IgA.Results Neonates of mothers who received a probiotic had higher CB IFN-gamma levels (P = 0.026), and a higher proportion had delectable blood IFN-gamma levels, compared with the placebo group (P = 0.034), although levels were undetectable in many infants. While this pattern was evident for both probiotics, when examined separately only the L. rhamnosus HN001 group showed statistically significant higher IFN-gamma levels (P = 0.030) compared with the placebo group. TGF-beta 1 levels were higher in early breast milk (week 1) from the probiotic groups (P = 0.028). This was evident for the B. lactis HN019 group (P = 0.041) with a parallel trend in the L. rhamnosus HN001 group (P = 0.075). Similar patterns were seen for breast milk IgA, which was more readily detected in breast milk from both the B. lactis HN019 (P = 0.008) and the L. rhamnosus HN001 group (P = 0.011). Neonatal plasma sCD 14 levels were lower in the B. lactis HN019 group compared with the placebo group (P = 0.041).Conclusion The findings suggest that supplementation with probiotics in pregnancy has the potential to influence fetal immune parameters as well as immunomodulatory factors in breast milk.
AB - Background This study explored the effects of maternal probiotic supplementation on immune markers in cord blood (CB) and breast milk.Methods CB plasma and breast milk samples were collected from a cohort of women who had received daily supplements of either 6 x 10(9) CFU/day Lactobacillus rhamnosus HN001 (n = 34), 9 x 10(9) CFU/day Bifidobacterium lactis HN019 (n = 35) or a placebo (n = 36) beginning 2-5 weeks before delivery and continuing for 6 months in lactating women. CB plasma and breast milk (collected at 3-7 days, 3 months and 6 months postpartum) were assayed for cytokines (IL-13, IFN-gamma, IL-6, TNF-alpha, IL-10, TGF-beta 1) and sCD 14. Breast milk samples were also assayed for total IgA.Results Neonates of mothers who received a probiotic had higher CB IFN-gamma levels (P = 0.026), and a higher proportion had delectable blood IFN-gamma levels, compared with the placebo group (P = 0.034), although levels were undetectable in many infants. While this pattern was evident for both probiotics, when examined separately only the L. rhamnosus HN001 group showed statistically significant higher IFN-gamma levels (P = 0.030) compared with the placebo group. TGF-beta 1 levels were higher in early breast milk (week 1) from the probiotic groups (P = 0.028). This was evident for the B. lactis HN019 group (P = 0.041) with a parallel trend in the L. rhamnosus HN001 group (P = 0.075). Similar patterns were seen for breast milk IgA, which was more readily detected in breast milk from both the B. lactis HN019 (P = 0.008) and the L. rhamnosus HN001 group (P = 0.011). Neonatal plasma sCD 14 levels were lower in the B. lactis HN019 group compared with the placebo group (P = 0.041).Conclusion The findings suggest that supplementation with probiotics in pregnancy has the potential to influence fetal immune parameters as well as immunomodulatory factors in breast milk.
U2 - 10.1111/j.1365-2222.2008.03061.x
DO - 10.1111/j.1365-2222.2008.03061.x
M3 - Article
C2 - 18631345
SN - 0954-7894
VL - 38
SP - 1606
EP - 1614
JO - Clinical and Experimental Allergy
JF - Clinical and Experimental Allergy
IS - 10
ER -